Cormorant Asset Management, LP and Bihua Chen filed Amendment No. 5 to their Schedule 13G with the SEC on November 2, 2026, disclosing a combined beneficial ownership position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) as of October 31, 2026.

Key Highlights

  • Beneficial ownership: Each reporting person discloses 1,500,000 shares of Corbus Pharmaceuticals common stock beneficially owned in aggregate.
  • Percent of class: The 1,500,000 shares represent 7.76% of the issuer's outstanding common stock, according to the filing.
  • Voting and dispositive power: Both Cormorant Asset Management, LP and Bihua Chen report zero sole voting or dispositive power, and 1,500,000 shares of shared voting and shared dispositive power each.
  • Underlying fund: The shares are held by Cormorant Global Healthcare Master Fund, LP, for which Cormorant serves as investment manager and Bihua Chen serves as managing member of the general partner.
  • Share count basis: The percentage figure is calculated against 19,341,293 shares of common stock outstanding as of August 4, 2026, per the issuer's quarterly report filed August 6, 2026.
  • Event date: The event requiring this filing occurred on October 31, 2026.

Cormorant and Chen Disclose 7.76% Stake in Corbus Pharmaceuticals

According to the filing, Cormorant Asset Management, LP, a Delaware limited partnership operating as an investment adviser, and Bihua Chen, a United States citizen, jointly submitted Amendment No. 5 to their Schedule 13G on November 2, 2026. Both reporting persons list their address as 200 Clarendon Street, 50th Floor, Boston, MA 02116. Corbus Pharmaceuticals Holdings, Inc., the issuer, is a pharmaceutical company headquartered at 500 River Ridge Drive, Norwood, Massachusetts 02062, whose common stock carries a par value of $0.0001 per share and trades under CUSIP number 21833P301.

The filing states that the 1,500,000 shares reported are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund, while Cormorant Asset Management, LP serves as investment manager. Bihua Chen serves as managing member of the general partner entity and as general partner of Cormorant Asset Management, LP. The filing further discloses that "the Master Fund has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares." Each reporting person disclaims beneficial ownership of the reported shares "except to the extent of its or her pecuniary interest therein," as stated in the filing.

The percentage of class, 7.76%, is derived from the 19,341,293 shares of common stock reported as outstanding in the issuer's quarterly report for the period ended June 30, 2026, filed with the SEC on August 6, 2026. The filing indicates the securities were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.

What Was Disclosed

Amendment No. 5 to a Schedule 13G filed November 2, 2026 discloses that Cormorant Asset Management, LP and Bihua Chen each report beneficial ownership of 1,500,000 shares of Corbus Pharmaceuticals Holdings, Inc. common stock, equal to 7.76% of the outstanding class, held through the Cormorant Global Healthcare Master Fund, LP.